TP53 Mutations Promote Immunogenic Activity in Breast Cancer
Figure 8
TP53-mutated breast cancers (BCs) more highly express immune checkpoint genes and have a worse 20-year survival than TP53-wildtype BCs and associated with unfavorable survival prognosis in BC, while higher degree of immune cell infiltration is associated with a 20-year better survival prognosis in BC. (a) A number of important immune checkpoint genes are upregulated in TP53-mutated BCs versus TP53-wildtype BCs. (b) Kaplan-Meier survival curves show that TP53-mutated BCs have a worse 20-year survival prognosis than TP53-wildtype BCs. (c) Kaplan-Meier survival curves show that higher degree of immune cell infiltration is associated with a better 20-year survival prognosis in TP53-mutated BCs. The log-rank test P<0.05 indicates the significance of survival-time differences between two classes of patients.